DVC’s Negligence Claim Against Lonza Dismissed, Breach Claim to Be Amended

Dynport Vaccine Co. failed to show that defendant Lonza Biologics Inc. was negligent or unjustly enriched in a lawsuit claiming nonperformance of a botulinum neurotoxin vaccine manufacturing contract, a federal district court held April 30 in dismissing those claims (Dynport Vaccine Co. LLC v. Lonza Biologics, Inc., D. Md., 1:14-cv-02921-JKB, 4/30/15).

The U.S. District Court for the District of Maryland didn’t dismiss DVC’s breach of contract claim, however, and granted Lonza’s alternative motion for a clearer statement of the claim due to disagreements as to what constituted a legally binding agreement between the parties.

DVC is asking ...